Physician profile
Jose Benitez
NPI 1962530691
$2,212.17
in general payments reported to CMS, 2019-2025
26 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $169 · 2021: $421 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $369.91 | 2019-2021 | |
| Pfizer INC. | $313.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $205.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $161.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $129.57 | 2019-2021 | |
| Galderma Laboratories, L.P. | $124.48 | 2025 | |
| Novo Nordisk INC | $121.88 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.06 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $69.38 | 2019 | |
| Daiichi Sankyo INC. | $67.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.57 | 2019 | |
| Glaxosmithkline, LLC. | $57.54 | 2019 | |
| Amgen INC. | $49.82 | 2019 | |
| Astellas Pharma US INC | $49.75 | 2019 | |
| Napo Pharmaceuticals INC | $42.25 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $40.57 | 2019 | |
| Allergan, INC. | $34.76 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $34.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.03 | 2019 | |
| Merck Sharp & Dohme LLC | $25.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.39 | 2019 | |
| Abbvie INC. | $19.93 | 2019 | |
| Amarin Pharma, INC. | $17.01 | 2019 | |
| Assertio Therapeutics, INC. | $16.04 | 2019 | |
| Genentech USA, INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.